Surgical Innovations Group PLC 5-year USA distribution agreement (0224P)
February 15 2021 - 2:00AM
UK Regulatory
TIDMSUN
RNS Number : 0224P
Surgical Innovations Group PLC
15 February 2021
Surgical Innovations Group plc
("Surgical Innovations", "SI" or the "Company")
5-year USA distribution agreement
Distribution agreement signed with Microline Surgical Inc for
YelloPort+Plus(TM) and YelloPort Elite(TM)
Surgical Innovations Group plc (AIM: SUN), the designer,
manufacturer and distributor of innovative medical technology for
minimally invasive surgery ("MIS"), announces a new USA
distribution agreement with Microline Surgical Inc. ("Microline")
for the Company's range of YelloPort+Plus(TM) and YelloPort
Elite(TM) Access Devices. The 5-year agreement brings a significant
opportunity to SI for growth in the US Trocar market.
Microline's sales & marketing structure is ideally placed to
leverage their experience with Resposable surgical instruments to
effectively drive US sales of YelloPort+Plus(TM) and YelloPort
Elite(TM) Access Devices.
Based near Boston, MA, U.S.A. Microline designs, manufactures
and distributes high quality instruments aimed at the MIS market.
Its portfolio of products is complementary to those offered by SI
with a focus on the resposable ethos of cost and sustainability. SI
has a long established relationship with Microline, where it has an
exclusive GB distribution agreement for Microline instruments that
are complementary to the SI branded range.
Timothy Gehlmann, President & CEO of Microline, noted:
"Microline is excited to add the YelloPort line of trocars from SI
to our product portfolio. The SI trocar line complements our MIS
instrument line by broadening our solution offering to
customers."
Adam Power, Group Development Director at SI, added: "The United
States accounts for almost half of the worldwide trocar market.
Microline has a direct sales team with considerable experience in
the selling of Resposable surgical devices. Microline and Surgical
Innovations, through its UK subsidiary Elemental Healthcare, share
a long history of synergy and growth and we are very excited to
replicate this successful relationship in the United States."
For further information please contact:
Surgical Innovations Group plc www sigroupplc com
David Marsh, CEO Tel: 0113 230 7597
Charmaine Day, Co Sec & GFC
N+1 Singer (Nominated Adviser Tel: 020 7496 3000
& Broker)
Aubrey Powell / Rachel Hayes/
Iqra Amin
Walbrook PR (Financial PR & Investor Tel: 020 7933 8780 or si@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391
303
About Surgical Innovations Group plc
The Group specialises in the design, manufacture, sale and
distribution of innovative, high quality medical products,
primarily for use in minimally invasive surgery. Our product and
business development is guided and supported by a key group of
nationally and internationally renowned surgeons across the
spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access
systems, surgical instruments and retraction devices which are sold
directly in the UK home market through our subsidiary, Elemental
Healthcare, and exported widely through a global network of trusted
distribution partners. Many of our products in this field are based
on a "resposable" concept, in which the products are part
re-usable, part disposable, offering a high quality and
environmentally responsible solution at a cost that is competitive
against fully disposable alternatives.
Elemental also has exclusive UK distribution for a select group
of specialist products employed in laparoscopy, bariatric and
metabolic surgery, hernia repair and breast reconstruction.
In addition, we design and develop medical devices for carefully
selected OEM partners, and have also collaborated with a major UK
industrial partner to provide precision engineering solutions to
complex problems outside the medical arena.
We aim for our brands to be recognised and respected by
healthcare professionals in all major geographical markets in which
we operate and provide by development, partnership or acquisition a
broad portfolio of cost effective, procedure specific surgical
instruments and implantable devices that offer reliable solutions
to genuine clinical needs in the operating theatre environment.
The Group currently employs approximately 100 people across two
sites in the UK. Product design, engineering and manufacturing are
carried out at the SI site in Yorkshire. Commercial activities
including marketing, UK distribution and international sales and
marketing are based at Elemental Healthcare in Berkshire.
Further information
Further details of the Group's businesses and products are
available on the following websites:
www sigroupplc com
www surginno com
www elementalhealthcare co.uk
To receive regular updates by email, please contact
si@walbrookpr.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRFLFSVFRISLIL
(END) Dow Jones Newswires
February 15, 2021 02:00 ET (07:00 GMT)
Surgical Innovations (LSE:SUN)
Historical Stock Chart
From Apr 2024 to May 2024
Surgical Innovations (LSE:SUN)
Historical Stock Chart
From May 2023 to May 2024